A Study to Determine How BI 907828 (Brigimadlin) is Taken up in the Tumor (Phase 0) and to Determine the Highest Dose of BI 907828 (Brigimadlin) That Could be Tolerated (Phase 1a) in Combination With Radiation Therapy in People With a Brain Tumor Called Glioblastoma

Glioblastoma Clinical Trial

Official title:

A Phase 0/Ia Study of BI 907828 (Brigimadlin) Concentrations in Brain Tissue and a Non-randomized Open-label, Dose Escalation Study of BI 907828 in Combination With Radiotherapy in Patients With Newly Diagnosed Glioblastoma

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05376800
• Other study ID #: 1403-0007
• Secondary ID: 2023-506409-20-0
• Status: Recruiting
• Phase: Phase 1
• Start date: November 30, 2022
• Est. completion date: December 20, 2027

Study information

• Verified date: April 2024
• Source: Boehringer Ingelheim
• Contact: Boehringer Ingelheim
• Phone: 1-800-243-0127
• Email: clintriage.rdg[@]boehringer-ingelheim.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is open to adults with newly diagnosed glioblastoma, a type of brain tumor. The study has two parts. Part 1 is open to people who can get their brain tumor removed by surgery. Part 2 is open to people who already had such a brain surgery.

This study tests a medicine called BI 907828 (Brigimadlin). BI 907828 (Brigimadlin) is a socalled MDM2 inhibitor that is being developed to treat cancer.

The purpose of Part 1 of the study is to find out how BI 907828 (Brigimadlin) is taken up in the tumor. Participants take a single dose of BI 907828 (Brigimadlin) as a tablet before the brain surgery. Part 1 of the study takes about 1 month. During this time, participants have their brain tumor removed by surgery and visit the study site about 8 times.

The purpose of Part 2 is to find the highest dose of BI 907828 (Brigimadlin) that the participants can tolerate in combination with standard radiation therapy. During the first 6 weeks, participants get standard radiation therapy. In addition, they take a dose of BI 907828 (Brigimadlin) once every 3 weeks. Participants may continue to take BI 907828 (Brigimadlin) as long as they benefit from treatment and can tolerate it. They visit the study site regularly.

During the entire study, doctors also regularly check participants' health and take note of any unwanted effects.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 35
• Est. completion date: December 20, 2027
• Est. primary completion date: November 1, 2027
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion criteria

• Inclusion criteria Part Phase 0:

• Histologically (if prior biopsy) or radiologically diagnosed glioblastoma.

• Neurosurgical tumor resection is indicated and planned according to the assessment of the treating physician.

• Patients must be at least 18 years old.

• Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1 (an ECOG of 2 is acceptable, if it is due to non-cancer-related disability, and after agreement with the sponsor).

• Inclusion criteria Part Phase Ia:

• Histologically demonstrated diagnosis of TP53 wild type glioblastoma harboring unmethylated O6-methylguanine-DNA-methyltransferase (MGMT) promoters. Glioblastoma definition according to 2021 World Health Organization (WHO) Classification of Central Nervous System (CNS) tumors, i.e. IDH- wild type only.

• Patient has undergone neurosurgical tumor resection and is eligible for standard radiotherapy.

• Patients must be neurologically stable based on the judgement of the treating physician. The use of corticosteroids and anti-seizure medication is allowed and should be at a stable or decreasing dose for at least 7 days before inclusion in the trial. Anti-seizure medication should not include agents that interact with BI 907828 (Brigimadlin).

• For patients, who have participated in Phase 0, the interval between the single dose of BI 907828 (Brigimadlin) and subsequent Phase 1a treatment must be at least 21 days.

Further inclusion criteria applies.

Exclusion criteria

• Exclusion criteria Part Phase 0:

• Known TP53 mutant glioblastoma (Note: testing is not mandatory for inclusion).

• Known Isocitrate dehydrogenase (IDH) mutant grade IV astrocytoma (Note: testing is not mandatory for inclusion).

• Patient who must receive or intends to receive restricted medications.

• Patients with pacemakers or other metallic implants that can interfere with the magnetic field during Magnetic Resonance Imaging (MRI) investigations.

• Inability to undergo contrast-enhanced MRI (Glomerular Filtration Rate (GFR) <30 mL/min).

• Exclusion criteria Part Phase Ia:

• Patients who have received previous systemic therapy (with the exception of patients who participated in Phase 0) or radiotherapy for glioblastoma.

• Patients who must or intend to continue the intake of restricted medications or any drug considered likely to interfere with the safe conduct of the trial.

• Patients with pacemakers or other metallic implants that can interfere with the magnetic field during MRI investigations.

• Inability to undergo contrast-enhanced MRI (GFR <30 mL/min). Further exclusion criteria applies.

Related Conditions & MeSH terms

• Glioblastoma

Intervention

Drug:
• BI 907828 (Brigimadlin)
BI 907828 (Brigimadlin)

Locations

Country	Name	City	State
Belgium	UZ Leuven	Leuven
Spain	Hospital del Mar	Barcelona
Spain	Hospital Universitario 12 de Octubre	Madrid
United States	Mayo Clinic Cancer Center	Jacksonville	Florida
United States	Yale New Haven Hospital	New Haven	Connecticut
United States	Mayo Clinic-Arizona	Phoenix	Arizona
United States	Mayo Clinic, Rochester	Rochester	Minnesota

Sponsors (1)

Lead Sponsor	Collaborator
Boehringer Ingelheim

Countries where clinical trial is conducted

United States,  Belgium,  Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Phase 0: Measured total concentration of BI 907828 (Brigimadlin) in brain tissue homogenate from noncontrast enhancing and contrast enhancing brain tumor regions	Brain tissue samples will be collected after standard of care neurosurgical tumor resection.; Concentration of BI 907828 (Brigimadlin) will be quantitated in nanomole/kilogram (nmol/Kg) of tissue by validated liquid chromatography mass spectrometry (LC/MS) method.	Up to 24 hours (h)
Primary	Phase 0: Calculated unbound concentration of BI 907828 (Brigimadlin) in brain tissue homogenate from noncontrast enhancing and contrast enhancing brain tumor regions	Brain tissue samples will be collected after standard of care neurosurgical tumor resection.; Concentration of BI 907828 (Brigimadlin) will be quantitated in nanomole/kilogram (nmol/Kg) of tissue by validated liquid chromatography mass spectrometry (LC/MS) method.	Up to 24 hours (h)
Primary	Phase Ia: Occurrence of dose-limiting toxicity (DLT), graded according to Common Terminology Criteria for Adverse Events version 5.0, during the Maximum Tolerated Dose (MTD) evaluation period		Up to 63 Days
Primary	Phase Ia: Occurrence of adverse events (AEs) graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 during the entire treatment period		Up to 7 months.
Secondary	Phase 0: Dose-dependent changes of expression levels of Tumor suppressor protein p53 (TP53) target genes in contrast enhancing brain regions and non-contrast enhancing brain regions		Up to 24 hours (h)
Secondary	Phase Ia: Progression-free survival (PFS)		Up to 8 months.
Secondary	Phase Ia: Maximum plasma concentration (Cmax) of BI 907828 (Brigimadlin) in plasma at Cycle 1		Up to Day 17
Secondary	Phase Ia: Area under the Curve of BI 907828 (Brigimadlin) in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz)		Up to Day 17
Secondary	Phase Ia: Area under the Curve of BI 907828 (Brigimadlin) in plasma over the time interval from 0 extrapolated to infinity (AUC0-8)		Up to Day 17

External Links

•   Related Info